Labcorp Drug Testing
ViroLogic to Provide Phenotypic HIV Drug Resistance Testing Through LabCorp's Nationwide Laboratory Network Business/Medical Editors
SOUTH SAN FRANCISCO--(BW HealthWire)--March 23, 2000
Agreement Increases Physician and Patient Access to
PhenoSense(TM)HIV Assay
ViroLogic, Inc. announced today that PhenoSense(TM) HIV, the Company's phenotypic drug resistance assay, is now available through the national laboratory services network of Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH). Under the terms of the agreement, ViroLogic will perform the PhenoSense HIV assay on specimens referred by LabCorp.
Today's agreement will provide physicians and patients access to PhenoSense HIV through LabCorp's network of 900 Patient Service Centers and 25 major laboratories across the country. LabCorp offers more than 2,000 clinical tests, including sophisticated molecular diagnostics in the area of infectious diseases.
PhenoSense HIV, launched in 1999, is already available through three other major clinical reference laboratories in the United States - Quest Diagnostics, Specialty Laboratories and American Medical Laboratories (AML).
About ViroLogic, Inc.
ViroLogic is a biotechnology company developing and marketing innovative products to guide and improve treatment of viral diseases. The Company has developed a practical way of directly measuring the impact of genetic mutations on drug resistance and using this information to guide therapy. The Company has a proprietary technology, called PhenoSense(TM), for testing drug resistance in viruses that cause serious diseases such as AIDS, hepatitis B and hepatitis C. The Company's first product, PhenoSense HIV, is a test that directly and quantitatively measures resistance of a patient's HIV to anti-viral drugs. The Company is also developing PhenoSense products for other viral diseases and intends to use the results of its PhenoSense tests and other clinical data to develop its Therapy Guidance System(TM) (TGS(TM)), an interactive database to help physicians guide patient therapy.
Statements in the Company's press releases, reports and information disclosures about its products, including PhenoSense HIV, and their prospects for development and commercialization, other than statements of historical facts, are forward-looking statements and are subject to a number of uncertainties that may cause actual events or results to differ materially from the statements made. Factors that could affect actual events or results include risks associated with performance under the Company's agreements with third parties, research and development progress, competitive products, and the strength of the Company's patent portfolio.
COPYRIGHT 2000 Business Wire
COPYRIGHT 2000 Gale Group
|
